Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Herbal granules aim to lift mood in transplant survivors

NCT ID NCT07608029

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Xiaochaihu Granules, a traditional Chinese herbal medicine, can help with depression in people who have had a stem cell transplant. About 46 patients will receive either a low or high dose of the granules for 100 days, alongside standard care. Researchers will track mood changes, side effects, and transplant-related complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xiaochaihu Granules (a traditional Chinese medicine herbal formula)
What this could lead to
If it works, this could offer a new option to ease depression in people recovering from a stem cell transplant, without adding strong side effects.
What could go wrong
This is a small, early-phase trial with only 46 people, so results may not apply widely. The herbal granules may not work better than standard care, and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the following criteria: 1. Able to understand the study procedures and voluntarily provide written informed consent (or consent from a legal guardian where applicable); 2. Age ≥14 years, male or female; 3. Patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT); 4. Newly diagnosed depression after allo-HSCT, assessed by standardized scales (e.g., HADS and/or HAMD); 5. Evidence of successful neutrophil engraftment prior to enrollment; 6. Willing and able to comply with study procedures and follow-up assessments. Exclusion Criteria: 1. Refusal to participate in the study; 2. Presence of severe psychiatric disorders or severe somatic symptom disorders; 3. Known allergy to Xiaochaihu Granules or any of its components; 4. Current use of other antidepressant medications; 5. Severe organ dysfunction or unstable clinical condition, including but not limited to: Uncontrolled bloodstream infection; Expected survival \<3 months; 6. History of splenectomy; 7. Renal insufficiency with serum creatinine ≥2.0 mg/dL; 8. Cholestatic liver disease or unresolved hepatic veno-occlusive disease (VOD); 9. Significant cardiovascular conditions, including: Unstable angina; Acute myocardial infarction within 6 months prior to enrollment; NYHA class III-IV heart failure; Circulatory failure requiring vasoactive or inotropic support; Clinically significant arrhythmia requiring treatment; 10. Severe respiratory disease requiring mechanical ventilation or ≥50% oxygen support; 11. Patients whose primary disease is in complete remission after transplantation (per protocol definition); 12. Participation in another interventional clinical trial within 21 days prior to enrollment (or within 5 half-lives of the investigational product, whichever is longer); 13. Any other condition deemed by the investigator to make the patient unsuitable for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, secondary are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

depressive disorder Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.